The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
FDA approval of ropeginterferon alfa-2b-njft for the treatment of adult patients with polycythemia vera
On November 12, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft, a monopegylated, long-acting interferon, for the treatment of adult patients with polycythemia vera. The decision was based on results from the PEGINVERA (NCT01193699) and PROUD/CONTINUATION-PV studies (NCT01949805 and NCT02218047, respectively).1
After 7.5 years of treatment, complete hematologic response, which was defined as a hematocrit of <45% without phlebotomy for at least 2 months, a platelet count ≤400 × 109/L, a leukocyte count ≤10 × 109/L, and a normal spleen size (longitudinal diameter ≤12 cm for females and ≤13 cm for males), was achieved in 61% of patients in the PEGINVERA trial. Also, based on objective laboratory parameters only, (with the exclusion of normal spleen size and thrombosis), a hematologic response was achieved in 80% of patients.1
Pooled safety data from the trials showed serious adverse reactions with an incidence >4% included urinary tract infections, transient ischemic attacks, and depression; while the most common adverse reactions, with an incidence >40%, included influenza-like illness, arthralgia, fatigue, pruritis, nasopharyngitis, and musculoskeletal pain.1
The recommended dose of ropeginterferon alfa-2b-njft is once every 2 weeks until hematologic parameters are stabilized. After a year, those with a stable complete hematologic response can be treated once every 4 weeks. This allows a flexible dosing that can help meet the individual needs of a patient.1
Ropeginterferon alfa-2b-njft has previously received orphan drug designation by the FDA and is already approved in Europe, Taiwan, and South Korea for this indication.1
For more information on the 5-year results from the PROUD-PV and CONTINUATION-PV studies read our summary article here.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content